Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06575257 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 28, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Xijing Hospital
179 trials monitored
See 8 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and pathological tumor volume with minimal residual disease (MRD)) as compared to ADT.
Trial Details
NCT Number NCT06575257
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov